Gastrointestinal disturbances and their management in miglustat-treated patients. (Q33451316)

26 July 2017

1 reference

title

Gastrointestinal disturbances and their management in miglustat-treated patients. (English)

1 reference

26 July 2017

6

Eugen Mengel

1 reference

26 July 2017

Nadia Belmatoug

1

1 reference

26 July 2017

Alberto Burlina

2

1 reference

26 July 2017

Pilar Giraldo

3

1 reference

26 July 2017

Chris J Hendriksz

4

1 reference

26 July 2017

David J Kuter

5

1 reference

26 July 2017

Gregory M Pastores

7

1 reference

26 July 2017

21 July 2011

1 reference

Journal of Inherited Metabolic Disease

26 July 2017

1 reference

26 July 2017

34

1 reference

26 July 2017

991-1001

1 reference

26 July 2017

5

1 reference

https://scigraph.springernature.com/pub.10.1007/s10545-011-9368-7

26 July 2017

0 references

cites work

Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis.

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9368-7

Type 1 Gaucher's disease in the adult. Nutritional management during initiation of treatment with miglustat

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9368-7

Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9368-7

Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9368-7

Real-world clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL project

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9368-7

Low-dose N-butyldeoxynojirimycin (OGT 918) for type I Gaucher disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9368-7

Miglustat (Zavesca) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9368-7

Treatment with miglustat reverses the lipid-trafficking defect in Niemann-Pick disease type C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9368-7

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9368-7

Clinical experience with substrate reduction therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9368-7

Management and treatment of lactose malabsorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9368-7

Therapeutic goals in the treatment of Gaucher disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9368-7

An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9368-7

Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9368-7

Long-term miglustat therapy in children with Niemann-Pick disease type C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9368-7

Miglustat in patients with Niemann-Pick disease Type C (NP-C): a multicenter observational retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9368-7

Clinical experience with miglustat therapy in pediatric patients with Niemann-Pick disease type C: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9368-7

Improved lactose digestion and intolerance among African-American adolescent girls fed a dairy-rich diet.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9368-7

Control of jejunal sucrase and maltase activity by dietary sucrose or fructose in man. A model for the study of enzyme regulation in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9368-7

Randomized, controlled trial of miglustat in Gaucher's disease type 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9368-7

Miglustat in late-onset Tay-Sachs disease: a 12-month, randomized, controlled clinical study with 24 months of extended treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9368-7

Influence of food intake on the pharmacokinetics of miglustat, an inhibitor of glucosylceramide synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9368-7

New therapies in the management of Niemann-Pick type C disease: clinical utility of miglustat

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9368-7

Recommendations on the diagnosis and management of Niemann-Pick disease type C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9368-7

Miglustat in adult and juvenile patients with Niemann-Pick disease type C: long-term data from a clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9368-7

Critical role for glycosphingolipids in Niemann-Pick disease type C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10545-011-9368-7

N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis.

21 January 2018

1 reference

12 December 2020

The tolerability and pharmacokinetics of N-butyl-deoxynojirimycin in patients with advanced HIV disease (ACTG 100). The AIDS Clinical Trials Group (ACTG) of the National Institute of Allergy and Infectious Diseases

1 reference

12 December 2020

The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3.

1 reference

12 December 2020

N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo

1 reference

12 December 2020

Sugar-dependent selective induction of mouse jejunal disaccharidase activities

1 reference

12 December 2020

Short-term effect of miglustat in every day clinical use in treatment-naïve or previously treated patients with type 1 Gaucher's disease.

1 reference

12 December 2020

Dietary modifications in patients receiving miglustat.

1 reference

12 December 2020

Effect of diet on intestinal and pancreatic enzyme activities in the pig

1 reference

12 December 2020

Intestinal disaccharidase activities in relation to age, race, and mucosal damage

1 reference

12 December 2020

The effect of oral supplementation with Lactobacillus reuteri or tilactase in lactose intolerant patients: randomized trial.

1 reference

12 December 2020

10.1007/S10545-011-9368-7

Identifiers

DOI

1 reference

Dimensions Publication ID

26 July 2017

1047941320

0 references

Fatcat ID

release_eyreasmfsrdr7oax2aod7pe234

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/eyreasmfsrdr7oax2aod7pe234

24 November 2022

mapped directly with Wikidata item

1 reference